中华精神科杂志
中華精神科雜誌
중화정신과잡지
CHINESE JOURNA OF PSYCHIATRY
2010年
1期
19-23
,共5页
陈大春%修梅红%王宁%李艳丽%杨可冰%聂鹰%谭云龙%张向阳
陳大春%脩梅紅%王寧%李豔麗%楊可冰%聶鷹%譚雲龍%張嚮暘
진대춘%수매홍%왕저%리염려%양가빙%섭응%담운룡%장향양
精神分裂症%自由基%超氧化物歧化酶%丙二醛
精神分裂癥%自由基%超氧化物歧化酶%丙二醛
정신분렬증%자유기%초양화물기화매%병이철
Schizophrenia%Free radicals%Superoxide dismutase%Malondialdehyde
目的 探讨自由基、抗氧化酶在精神分裂症病理机制中的作用,并观察利培酮对抗氧化酶、丙二醛的影响.方法 符合美国精神障碍诊断与统计手册第4版诊断标准的精神分裂症首次发病(以下简称首发)住院患者90例(患者组),采用单一利培酮4～6 mg治疗,观察周期为12周,以阳性和阴性症状量表(PANSS)评定精神症状,并检测血清总抗氧化活力(TAC)、总超氧化物歧化酶(T-SOD)活力、铜锌超氧化物歧化酶(Cu-ZnSOD)活力、锰超氧化物歧化酶(Mn-SOD)活力及丙二醛(MDA)和S100B的含量.选择87名正常健康人作为对照(对照组).结果 患者组T-SOD(732±126)×102U/L,Cu-ZnSOD活力(578±175)×102U/L,S100B蛋白含量(180±181)ng/L,均显著高于对照组[(672±115)×102U/L,(440±148)×102U/L,(101±115)ng/L;t=3.2,5.6,2.2;v=169,169,60;P均<0.05].而Mn-SOD活力[(153±145)×102 U/L]显著低于对照组[(232±161)×102 U/L;t=-3.3,v=169,P<0.05].治疗后TAC活力[(150±54)×102 U/L]较治疗前[(174±59)×102U/L]显著提高;t=-2.6,v=66,P<0.05.治疗前Mn-SOD与PANSS总分减分值可建立回归方程(R=0.62,R2=0.38,F=7.89,P=0.02);治疗前TAC与阳性症状减分值可建立回归方程(R=0.71,R2=0.50,F=12.9,P=0.00);治疗前Mn-SOD、治疗前后TAC差值与阴性症状减分值可建立回归方程(R=0.76,R2=0.58,F=8.24,P=0.00).结论 自由基代谢、氧化应激可能参与精神分裂症发病机制;利醅酮提高了首发患者的总抗氧化活力.
目的 探討自由基、抗氧化酶在精神分裂癥病理機製中的作用,併觀察利培酮對抗氧化酶、丙二醛的影響.方法 符閤美國精神障礙診斷與統計手冊第4版診斷標準的精神分裂癥首次髮病(以下簡稱首髮)住院患者90例(患者組),採用單一利培酮4～6 mg治療,觀察週期為12週,以暘性和陰性癥狀量錶(PANSS)評定精神癥狀,併檢測血清總抗氧化活力(TAC)、總超氧化物歧化酶(T-SOD)活力、銅鋅超氧化物歧化酶(Cu-ZnSOD)活力、錳超氧化物歧化酶(Mn-SOD)活力及丙二醛(MDA)和S100B的含量.選擇87名正常健康人作為對照(對照組).結果 患者組T-SOD(732±126)×102U/L,Cu-ZnSOD活力(578±175)×102U/L,S100B蛋白含量(180±181)ng/L,均顯著高于對照組[(672±115)×102U/L,(440±148)×102U/L,(101±115)ng/L;t=3.2,5.6,2.2;v=169,169,60;P均<0.05].而Mn-SOD活力[(153±145)×102 U/L]顯著低于對照組[(232±161)×102 U/L;t=-3.3,v=169,P<0.05].治療後TAC活力[(150±54)×102 U/L]較治療前[(174±59)×102U/L]顯著提高;t=-2.6,v=66,P<0.05.治療前Mn-SOD與PANSS總分減分值可建立迴歸方程(R=0.62,R2=0.38,F=7.89,P=0.02);治療前TAC與暘性癥狀減分值可建立迴歸方程(R=0.71,R2=0.50,F=12.9,P=0.00);治療前Mn-SOD、治療前後TAC差值與陰性癥狀減分值可建立迴歸方程(R=0.76,R2=0.58,F=8.24,P=0.00).結論 自由基代謝、氧化應激可能參與精神分裂癥髮病機製;利醅酮提高瞭首髮患者的總抗氧化活力.
목적 탐토자유기、항양화매재정신분렬증병리궤제중적작용,병관찰리배동대항양화매、병이철적영향.방법 부합미국정신장애진단여통계수책제4판진단표준적정신분렬증수차발병(이하간칭수발)주원환자90례(환자조),채용단일리배동4～6 mg치료,관찰주기위12주,이양성화음성증상량표(PANSS)평정정신증상,병검측혈청총항양화활력(TAC)、총초양화물기화매(T-SOD)활력、동자초양화물기화매(Cu-ZnSOD)활력、맹초양화물기화매(Mn-SOD)활력급병이철(MDA)화S100B적함량.선택87명정상건강인작위대조(대조조).결과 환자조T-SOD(732±126)×102U/L,Cu-ZnSOD활력(578±175)×102U/L,S100B단백함량(180±181)ng/L,균현저고우대조조[(672±115)×102U/L,(440±148)×102U/L,(101±115)ng/L;t=3.2,5.6,2.2;v=169,169,60;P균<0.05].이Mn-SOD활력[(153±145)×102 U/L]현저저우대조조[(232±161)×102 U/L;t=-3.3,v=169,P<0.05].치료후TAC활력[(150±54)×102 U/L]교치료전[(174±59)×102U/L]현저제고;t=-2.6,v=66,P<0.05.치료전Mn-SOD여PANSS총분감분치가건립회귀방정(R=0.62,R2=0.38,F=7.89,P=0.02);치료전TAC여양성증상감분치가건립회귀방정(R=0.71,R2=0.50,F=12.9,P=0.00);치료전Mn-SOD、치료전후TAC차치여음성증상감분치가건립회귀방정(R=0.76,R2=0.58,F=8.24,P=0.00).결론 자유기대사、양화응격가능삼여정신분렬증발병궤제;리배동제고료수발환자적총항양화활력.
Objective To explore the role of antioxidant enzymes and free radicals in the pathogensis of schizophrenia and effects of risperidone treatment.Methods Ninety first-episode schizophrenia inpatients according to the Dignostic and Statistical Manual of Mental Disorder Fouth Edition,were treated only with risperidone, observed for 12 weeks, and the clinical effects estimated with the Positive and Negative Syndrome Scale (PANSS).The biological markers including total anti-oxidant activity (TAC), total superoxide dismutase (T-SOD), cupro-zinc superoxide dismutase (Cu-ZnSOD), manganecesuperoxide dismutase (Mn-SOD), malondialdehyde (MDA) and S100B, were measured both in patients and controls (87 subjects).Results Activity of T-SOD and Cu-ZnSOD, S100B were significant increased in patients compare to controls [(732±126)×102U/Lvs.(672±115)×102 U/L;(578±175)×102 U/Lvs.(440±148)×102 U/L;(180±181) ng/Lvs.(101±115)ng/L;t=3.2, 5.6, 2.2;v=169,169, 60; P< 0.05].Mn-SOD activity was marked lower in patients compared to controls [(153±145)×102U/Lvs.(232±161)×102 U/L,t=-3.3,v =169, P<0.05].TAC activity was higher posttreatment compare to baseline [(150 ± 54)×102 U/L vs.( 174 ± 59)×102 U/L; t = - 2.6,v= 66,P<0.05].Mn-SOD activity in pre-treatment set up the regression equation with the improvement of PANSS total score(R =0.62 ,R2 = 0.38, F = 7.89, P = 0.02).TAC activity in pre-treatment set up the regression equation with the improvement of positive symptoms ( R = 0.71, R2 = 0.50,F=12.9,P = 0.00).Mn-SOD activity in pre-treatment and the changes in TAC between post-treatment and pre-treatment set up regression equation with the improvement negative symptoms( R =0.76, R2 = 0.58, F = 8.24, P = 0.00).Conclusion The free radicals and antioxidant enzymes may be involved in the pathology of schizophrenia, and risperidone treatment may improve antioxidant activity of first-episode schizophrenic patients.
